AbbVie receives EU approval for Tepkinly for follicular lymphoma

6. Jul 2026

(AWP Alliance News) - AbbVie Inc on Monday said the European Commission had approved Tepkinly for the treatment of adult patients with relapsed or refractory follicular lymphoma.

The Chicago-based biopharmaceutical company said the approval covers Tepkinly in combination with enalidomide and rituximab.

The decision by the EC makes Tepkinly "the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the second-line setting, offering a chemotherapy-free option," said AbbVie.

The approval is based on results from the phase three Epcore FL-1 trial, which studied the effects of Tepkinly plus enalidomide and rituximab. The trial demonstrated a 79% reduction in disease progression or death when compared to treating the disease with rituximab alone.

"This approval is important because it brings an effective treatment option to patients across Europe, representing meaningful progress for patients with follicular lymphoma," said Roopal Thakkar, executive vice president of Research and Development and chief scientific officer at AbbVie.

Shares in AbbVie closed down 2.4% at USD254.76 each in New York on Monday.

By John Robaina, Alliance News reporter

Comments and questions to newsroom [at] alliancenews.com